MEDNAX

Pediatrix Medical Group, Inc. engages in the provision of physician services. It includes newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care. The company was founded by Roger J. Medel in 1979 and is headquartered in Sunrise, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MEDNAX reports stable Q4 performance, eyes in-network growth opportunities

MEDNAX's Q4 call highlighted stable performance, strategic focus on core areas, and challenges from R1 transition and labor inflation. Opportunities in payer relationships, acquisitions, and organic growth are key for future success.

MEDNAX (MD) reports solid Q1 performance, eyes growth opportunities

MEDNAX's Q1 2023 performance showcased stability in patient volumes, pricing strength, and effective cost management. The company's focus on revenue cycle management and debt reduction yielded positive outcomes. Addressing challenges and seizing growth opportunities will be key for sustained success.

MEDNAX (MD) reports strong Q2 performance and eyes growth opportunities

MEDNAX (MD) delivers a solid performance in Q2 2023 with stable patient volumes, strong pricing, and cost efficiencies. The company's focus on improving AR collections, expanding clinics, and potential acquisitions positions it well for future growth.

MEDNAX reports Q3 earnings below forecast, revises full-year outlook

MEDNAX acknowledges disappointing Q3 results, plans structural changes to address challenges, and revises full-year adjusted EBITDA outlook. Despite facing operational challenges, the company shows strength in managing cash and negotiating subsidies with hospital partners.

MEDNAX meets Q4 expectations, eyes stable growth and cost efficiencies

MEDNAX's Q4 performance met expectations, with a focus on stabilizing margins and narrowing financial performance range. The company is poised for stable revenue growth in 2024, with opportunities to deploy capital for acquisitions and improve cost efficiencies. Challenges include stabilizing margins and addressing modest revenue growth expectations.

MEDNAX reports strong Q1 results, accelerates restructuring for growth

MEDNAX's Q1 performance reflects positive revenue growth and operational efficiency initiatives. While facing challenges in communicating practice exits and financial impacts, the company is well-positioned to capitalize on growth opportunities in core services. By focusing on restructuring and maintaining financial discipline, MEDNAX aims to drive continued progress throughout 2024.

MEDNAX surpasses Q2 expectations, focuses on strategic realignment for growth

MEDNAX's Q2 performance exceeded expectations with revenue growth and cost efficiencies driving results.
While facing challenges from restructuring, the company aims to capitalize on opportunities for margin improvement.
Maintaining financial outlook, appointing new leadership, and strategic shifts position MEDNAX for future growth.
Overall, MEDNAX's focus on operational enhancements and strategic realignment bode well for its financial health.

MEDNAX surpasses Q3 expectations with strategic initiatives driving growth

MEDNAX delivered strong Q3 performance with revenue growth, stable patient volumes, and successful operational transitions.
Strategic initiatives like portfolio restructuring and improved liquidity position highlight the company's focus on long-term sustainability.
While challenges like executing restructuring plans and managing liquidity exist, opportunities for growth and value creation are also present.
Overall, MEDNAX's financial outlook remains positive, supported by operational efficiency and prudent financial management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mednax (MD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 11.6% in 4 Weeks, Here's Why Mednax (MD) Looks Ripe for a Turnaround

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Mednax 2021 Second Quarter Conference Call/Webcast Scheduled for Friday, August 6, 2021

Mednax 2021 Second Quarter Conference Call/Webcast Scheduled for Friday, August 6, 2021

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Mednax Announces CVS Aetna Voluntarily Dismisses 2018 Litigation

Mednax Announces CVS Aetna Voluntarily Dismisses 2018 Litigation

The stock price of Mednax (NYSE: MD), a healthcare company that partners with hospitals, health systems, and health care facilities to offer specialized women and children clinical services, has seen a 5% drop over the last five trading days. Mednax's contract with CVS Aetna in Texas expired.

What's Next For Mednax Stock After The Recent 20% Rally?

MEDNAX's (MD) Q1 results reflect lower costs. However, the same is partly offset by softer revenues.

MEDNAX's (MD) Q1 Earnings Surpass Estimates, Decline Y/Y

MEDNAX, Inc. (MD) CEO Mark Ordan on Q1 2021 Results - Earnings Call Transcript

Investors are cheering the company's Q1 results.

Why Mednax Stock Is Soaring Today

Mednax (MD) delivered earnings and revenue surprises of 60.00% and 2.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Mednax (MD) Q1 Earnings and Revenues Beat Estimates

Elanco Animal Health Inc

ModivCare

Varied companies across the vast healthcare space might have been affected differently by the COVID crisis during the first quarter.

Healthcare Stock Q1 Earnings Due on May 7: ELAN, MD, MODV

Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Mednax (MD) Q1 Earnings Expected to Decline

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Mednax 2021 First Quarter Conference Call/Webcast Scheduled for Friday, May 7, 2021

Mednax 2021 First Quarter Conference Call/Webcast Scheduled for Friday, May 7, 2021

RESTON, Va., April 21, 2021 /PRNewswire/ -- Oteemo, Inc., a leader in DevSecOps transformation and cloud native application development, today announced its successful transformation effort with Mednax, Inc. (NYSE: MD), the national medical group specializing in prenatal, neonatal and pediatric services.

Oteemo Helps Mednax Reduce Deployment Time from Months to Minutes

Mednax (MD) reported earnings 30 days ago. What's next for the stock?

Mednax (MD) Up 31.6% Since Last Earnings Report: Can It Continue?

Mednax (MD) collaborates with NighLight with an aim to offer enhanced pediatric care in Texas.

Mednax (MD) Ties Up With NightLight to Offer Better Pediatric Care

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #healthcare--Mednax, Inc. (NYSE: MD), specializing in prenatal, neonatal and pediatric services, announced its affiliation with NightLight Pediatric Urgent Care

Mednax Expands Presence in Texas through Affiliation with Eight-Clinic Pediatric Urgent Care Practice

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Mednax to Present at Upcoming Investor Conferences

Mednax to Present at Upcoming Investor Conferences

MEDNAX's (MD) fourth-quarter results reflect muted revenues caused by the COVID-19 pandemic.

MEDNAX's (MD) Q4 Earnings Fall Shy of Estimates, Tumble Y/Y

MEDNAX's (MD) CEO Mark Ordan on Q4 2020 Results - Earnings Call Transcript

The company released its earnings report for the fourth quarter.

Why Mednax Stock Is Plunging Today

Mednax (MD) delivered earnings and revenue surprises of -19.35% and -8.64%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Mednax (MD) Q4 Earnings and Revenues Miss Estimates

Shares of Mednax (NYSE:MD) fell 0.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 72.53% year over year to $0.25, which missed the estimate of $0.36.

Recap: Mednax Q4 Earnings

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Mednax 2020 Fourth Quarter Conference Call/Webcast Scheduled for Thursday, February 18, 2021

Mednax 2020 Fourth Quarter Conference Call/Webcast Scheduled for Thursday, February 18, 2021

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #neoconference2021--The virtual NEO conference will continue its longstanding tradition of addressing key areas of neonatal management to improve newborn outcomes.

Mednax's NEO: The Conference for Neonatology Goes Virtual Feb. 15-19

OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Files First Data Breach Case Against MedNax, Inc. and Pediatrix Medical Group, a MedNax Company

Federman & Sherwood Files First Data Breach Case Against MedNax, Inc. and Pediatrix Medical Group, a MedNax Company

Riding high on its strategic efforts and cost-cutting measures, MEDNAX (MD) holds enough potential to reap benefits for investors.

News for MEDNAX Stock (MD)